Top-tier asset, cheap pricing, savvy tactics. And balloons
We’re Miffed Too
Recent flotations of Galderma and Douglas underscore that fund managers are still being selective
Tricky exits
A conservative directed-share program on its IPO risks leaving the Redditor army feeling left out
‘Inconsequential, parochial and mildly protectionist’
Tactical trial balloon or a real possibility?
More Goldman drama
Loss of chip company listing to New York shows why it’s time to revive London as an IPO venue
Placebo Advisers
It’s too late, Gary, now it’s too late
Block trade probe found serious misconduct but results in slap on the wrist
IPO deal recovery hinges on bridging the valuation gap
Timing is everything (except for the FCA)
Not just a cyclical blip?
Well that was a let-down
More doughnuts than a Krispy Kreme
You can see why some investors are ‘hopping mad’
An IPO crash course in equity, transparency and accountability
When stabilisation can become a money-spinner
It’s barely alive!
Sid’s missing, presumed dead
Fading flotation fortunes
Perhaps not the hero we want, but maybe the hero we need
“It’s one louder, isn’t it?”
International Edition